SciClone Pharmaceuticals, Inc.  

(Public, NASDAQ:SCLN)   Watch this stock  
Find more results for SciClone Pharmaceuticals, Inc
4.80
-0.02 (-0.33%)
Real-time:   1:13PM EDT
NASDAQ real-time data - Disclaimer
Currency in USD
Range 4.74 - 4.95
52 week 4.24 - 6.30
Open 4.83
Vol / Avg. 100,521.00/268,142.00
Mkt cap 247.38M
P/E 23.78
Div/yield     -
EPS 0.20
Shares 51.49M
Beta 2.20
Inst. own 58%
Aug 11, 2014
Q2 2014 SciClone Pharmaceuticals Inc Earnings Call - 4:30PM EDT - Add to calendar
Aug 11, 2014
Q2 2014 SciClone Pharmaceuticals Inc Earnings Release - 4:00PM EDT - Add to calendar
Jun 12, 2014
SciClone Pharmaceuticals, Inc. Annual Shareholder Meeting
Jun 3, 2014
SciClone Pharmaceuticals, Inc. at Jefferies Global Healthcare Conference
May 12, 2014
Q1 2014 SciClone Pharmaceuticals, Inc. Earnings Release
May 12, 2014
Q1 2014 SciClone Pharmaceuticals, Inc. Earnings Conference Call - Webcast
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '14) 2013
Net profit margin 15.56% 8.63%
Operating margin 17.55% 8.21%
EBITD margin - 12.29%
Return on average assets 9.41% 6.19%
Return on average equity 11.24% 7.57%
Employees 570 -
CDP Score - -

Address

Suite 900, 950 Tower Lane
FOSTER CITY, CA 94404-2125
United States - Map
+1-650-3583456 (Phone)
+1-650-3583469 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

SciClone Pharmaceuticals, Inc. (SciClone) is a specialty pharmaceutical company. The Company has a product portfolio of therapies for oncology, infectious diseases, cardiovascular, urological, respiratory and central nervous system disorders. The Company�s main product is ZADAXIN (thymalfasin), which is approved in over 30 countries, which is used for the treatment of hepatitis B virus (HBV), hepatitis C (HCV), as a vaccine adjuvant, and certain cancers. In China, thymalfasin is also included in the treatment guidelines issued by the Ministry of Health for liver cancer. SciClone�s marketed portfolio also includes Depakine, the prescribed broad-spectrum anti-convulsant in China; Tritace, an ACE inhibitor for the treatment of hypertension; Stilnox, a hypnotic for the short-term treatment of insomnia (marketed as Ambien in the United States), and Aggrastat, an intervention cardiology product. On April 18, 2011, the Company acquired NovaMed Pharmaceuticals, Inc.

Officers and directors

Jon S. Saxe Independent Chairman of the Board
Age: 77
Bio & Compensation  - Reuters
Friedhelm Blobel Ph.D. President, Chief Executive Officer, Director
Age: 65
Bio & Compensation  - Reuters
Wilson W. Cheung Chief Financial Officer, Senior Vice President - Finance, Secretary
Age: 45
Bio & Compensation  - Reuters
Hong Zhao Chief Executive Officer - China Operations
Age: 50
Bio & Compensation  - Reuters
Raymond A. Low CPA Vice President - Finance, Controller
Age: 56
Bio & Compensation  - Reuters
Charles Meng Vice President - Compliance, General Counsel
Age: 51
Bio & Compensation  - Reuters
Min Yin CPA Vice President - Internal Audit
Age: 42
Bio & Compensation  - Reuters
Lan Xie CPA Vice President Finance, China Chief Financial Officer
Age: 41
Bio & Compensation  - Reuters
Nancy T. Chang Ph.D. Independent Director
Age: 64
Bio & Compensation  - Reuters
Richard J. Hawkins Independent Director
Age: 65
Bio & Compensation  - Reuters